|
|
An error appeared in the IZ Express #1,614 story below distributed on Wednesday, February 2, 2022. The summary table of the schedule of COVID-19 vaccination for people with moderate to severe immunocompromise incorrectly listed the booster dose for Pfizer-BioNTech and Moderna COVID-19 vaccines as being due 5 months after dose 2: the correct timing is 5 months after dose 3.
The tables have been corrected on the IZ Express website and the corrected story is below. Please discard any printed versions of the original story. We regret the error.
Are you using the most current COVID-19 vaccination schedules? Check these tables to be sure.
It is a challenge to keep up with the frequent adjustments to COVID-19 vaccination schedules. Review these tables to be sure you are following the latest version (last updated by CDC on January 7) and that you are using the current Emergency Use Authorization (EUA) Fact Sheets for healthcare providers and vaccine recipients. Changes made since January 1 are noted in bold print. Moderna and Pfizer-BioNTech mRNA vaccines are preferred, except when mRNA vaccine is contraindicated or when the patient wants Janssen (Johnson & Johnson, J&J) vaccine after being informed of risks and benefits.
COVID-19 recommended schedule for the general population (y = years, w = weeks, mo = months):
| Age Range |
Product |
Primary Series |
Booster dose? * |
| 5 through 11 y |
Pfizer-BioNTech,
orange cap |
2 doses: 0, 3 w |
None |
| 12 through 17 y |
Pfizer-BioNTech,
purple or gray cap |
2 doses: 0, 3 w |
5 mo after dose 2 |
| 18 y or older |
Pfizer-BioNTech,
purple or gray cap |
2 doses: 0, 3 w |
5 mo after dose 2 |
| 18 y or older |
Moderna |
2 doses: 0, 4 w (100 mcg) |
5 mo after dose 2 (50 mcg) |
| 18 y or older |
Alternate:
Janssen (J&J) |
one dose |
2 mo (8 w) later |
COVID-19 recommended schedule for people with moderate to severe immunocompromise:
| Age Range |
Product |
Primary Series |
Booster dose? * |
| 5 through 11 y |
Pfizer-BioNTech,
orange cap |
3 doses: 0, 3 w, 7 w |
None |
| 12 through 17 y |
Pfizer-BioNTech,
purple or gray cap |
3 doses: 0, 3 w, 7 w |
5 mo after dose 3 |
| 18 y or older |
Pfizer-BioNTech,
purple or gray cap |
3 doses: 0, 3 w, 7 w |
5 mo after dose 3 |
| 18 y or older |
Moderna |
3 doses: 0, 4 w, 8 w
(100 mcg) |
5 mo after dose 3
(50 mcg) |
| 18 y or older |
Alternate:
Janssen (J&J) |
one dose |
2 mo (8 w) later |
* CDC recommends use of the same brand for each dose in the primary series. Any age-appropriate option may be used as the booster dose; mRNA vaccines are preferred.
FDA: EUA Fact Sheets, dates of current versions:
CDC Emergency Use Instructions (EUI) for use of Pfizer-BioNTech mRNA vaccine in people given vaccines not authorized in the United States:
The most current CDC COVID-19 vaccine standing order templates, dated 12 January 2022, are available from Immunize.org's standing order template main page.
Related Links:
Back to top
|
